Meet the Experts
Gain exclusive insights into microscope technology by attending one of our expert presentations. All presentations will be held in ZEISS Booth 539.
Surgeon-Controlled Robotics use for neurosurgical tumor surgery: discussion of added values and benefits
Nader Sanai, MD
Director of Neurosurgical Oncology, Barrow Neurological Institute, Arizona
Monday, October 9
The future of fluorescence technology in tumor surgery
Peter Nakaji, MD
Professor of Neurosurgery, Barrow Neurological Institute, Arizona
Monday, October 9
First-hand experience using KINEVO 900
Michael Lawton, MD
Chair, Department of Neurosurgery, and President and CEO of Barrow Neurological Institute, Arizona
Tuesday, October 10
The discussion may include information on products and features that are a work in progress, may require FDA 510(k) clearance and are subject to change. Future availability cannot be guaranteed.
These sessions may include discussion of a drug that is not approved in the United States as well as drug applications and device applications that are not cleared in the United States.
Lunch Symposium
What is the Evolution of Neurosurgery?
Explore how the Robotic Visualization System™ from ZEISS and imaging technology can aid neurosurgical workflows.
Moderator
A new era: neurosurgical workflow using advanced visualization technologies
Joshua B. Bederson, MD
Professor and System Chair, Department of Neurosurgery, Mount Sinai Health System, New York
Panel Speaker
ZEISS QEVO, the Micro-Inspection Tool, for use in tumor and vascular surgery
Peter Nakaji, MD
Professor of Neurosurgery, Barrow Neurological Institute, Arizona
Panel Speaker
Vascular surgery using Digital Hybrid Visualization: FLOW 800 with the KINEVO 900
Jonathan Russin, MD
Assistant Surgical Director, Center for Neurorestoration, Keck Medicine of USC, California
The discussion may include information on products and features that are a work in progress, may require FDA 510(k) clearance and are subject to change. Future availability cannot be guaranteed.
These sessions may include discussion of a drug that is not approved in the United States as well as drug applications and device applications that are not cleared in the United States.